Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Anthony E. Oro, M.D., Ph.D., is the Eugene and Gloria Bauer Professor of Dermatology, Associate Director of the Center for Definitive and Curative Medicine, and the co-director of the Child Health Research Institute. He is co-founder of the Program in Epithelial Biology, and an active member of the Institute for Stem Cell Biology and Regenerative Medicine, Children’s Health Research Institute, Bio-X, and the Program in Cancer Biology. His research interests encompass cancer genomics and tumor evolution, stem cell biology and hair/skin development and regeneration, and definitive molecular and cellular therapeutics. His clinical interests include hair biology, non-melanoma skin cancer, and stem cell-based therapies for genetic skin diseases.
View Full Biography »
Professional Summary
Professional Education
- Medical Education: University of California San Diego School of Medicine (1993) CA
- Residency: Stanford University Dermatology Residency (1997) CA
- Internship: Stanford University Internal Medicine Residency (1994) CA
- Board Certification: American Board of Dermatology, Dermatology (1998)
Administrative Appointments
- Assoc Director, Center for Definitive and Curative Medicine (2016 - Present)
- Co-Director, Child Health Research Institute (2017 - Present)
Publications
-
Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice
Aszterbaum, M., Epstein, J., Oro, A., Douglas, V., LeBoit, P. E., Scott, M. P., & Epstein, E. H. (1999). Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. NATURE MEDICINE, 5(11), 1285–1291. -
Hair cycle regulation of Hedgehog signal reception
Oro, A. E., & Higgins, K. (2003). Hair cycle regulation of Hedgehog signal reception. DEVELOPMENTAL BIOLOGY, 255(2), 238–48. -
Laminin-10 is crucial for hair morphogenesis
Li, J., Tzu, J., Chen, Y., Zhang, Y. P., Nguyen, N. T., Gao, J., … Marinkovich, M. P. (2003). Laminin-10 is crucial for hair morphogenesis. EMBO JOURNAL, 22(10), 2400–2410. -
MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription
Callahan, C. A., Ofstad, T., Horng, L., Wang, J. K., Zhen, H. H., Coulombe, P. A., & Oro, A. E. (2004). MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. GENES & DEVELOPMENT, 18(22), 2724–29. -
Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4
Gonzalez-Quevedo, R., Shoffer, M., Horng, L., & Oro, A. E. (2005). Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. JOURNAL OF CELL BIOLOGY, 168(3), 453–63. -
Conditional telomerase induction causes proliferation of hair follicle stem cells
Sarin, K. Y., Cheung, P., Gilison, D., Lee, E., Tennen, R. I., Wang, E., … Artandi, S. E. (2005). Conditional telomerase induction causes proliferation of hair follicle stem cells. NATURE, 436(7053), 1048–52. -
Dual degradation signals control Gli protein stability and tumor formation
Huntzicker, E. G., Estay, I. S., Zhen, H., Lokteva, L. A., Jackson, P. K., & Oro, A. E. (2006). Dual degradation signals control Gli protein stability and tumor formation. GENES & DEVELOPMENT, 20(3), 276–81. -
Mammalian variations on a theme: a Smo and Sufu surprise
Oro, A. E. (2006). Mammalian variations on a theme: a Smo and Sufu surprise. DEVELOPMENTAL CELL, 10(2), 156–58. -
Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation
Sneddon, J. B., Zhen, H. H., Montgomery, K., van de Rijn, M., Tward, A. D., West, R., … Brown, P. O. (2006). Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(40), 14842–47. -
The primary cilia, a 'Rab-id' transit system for hedgehog signaling
Oro, A. E. (2007). The primary cilia, a 'Rab-id' transit system for hedgehog signaling. CURRENT OPINION IN CELL BIOLOGY, 19(6), 691–96. -
A new role for an old friend: NFAT and stem cell quiescence
Oro, A. E. (2008). A new role for an old friend: NFAT and stem cell quiescence. CELL STEM CELL, 2(2), 104–6. -
Controlling hair follicle signaling pathways through polyubiquitination
Huntzicker, E. G., & Oro, A. E. (2008). Controlling hair follicle signaling pathways through polyubiquitination. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 128(5), 1081–87. -
Laminin-511 is an epithelial message promoting dermal papilla development and function during early hair morphogenesis
Gao, J., DeRouen, M. C., Chen, C.-H., Nguyen, M., Nguyen, N. T., Ido, H., … Marinkovich, M. P. (2008). Laminin-511 is an epithelial message promoting dermal papilla development and function during early hair morphogenesis. GENES & DEVELOPMENT, 22(15), 2111–24. -
The Primary Cilium: A Small Yet Mighty Organelle
DeRouen, M. C., & Oro, A. E. (2009). The Primary Cilium: A Small Yet Mighty Organelle. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129(2), 264–65. -
I-BAR protein antagonism of endocytosis mediates directional sensing during guided cell migration
Quinones, G. A., Jin, J., & Oro, A. E. (2010). I-BAR protein antagonism of endocytosis mediates directional sensing during guided cell migration. JOURNAL OF CELL BIOLOGY, 189(2), 353–67. -
BAR domain competition during directional cellular migration
Quinones, G. A., & Oro, A. E. (2010). BAR domain competition during directional cellular migration. CELL CYCLE, 9(13), 2522–28. -
MIM and Cortactin Antagonism Regulates Ciliogenesis and Hedgehog Signaling
Bershteyn, M., Atwood, S. X., Woo, W.-M., Li, M., & Oro, A. E. (2010). MIM and Cortactin Antagonism Regulates Ciliogenesis and Hedgehog Signaling. DEVELOPMENTAL CELL, 19(2), 270–83. -
Laminin-511 and integrin beta-1 in hair follicle development and basal cell carcinoma formation
DeRouen, M. C., Zhen, H., Tan, S. H., Williams, S., Marinkovich, M. P., & Oro, A. E. (2010). Laminin-511 and integrin beta-1 in hair follicle development and basal cell carcinoma formation. BMC DEVELOPMENTAL BIOLOGY, 10. -
In Vivo Imaging of Human and Mouse Skin with a Handheld Dual-Axis Confocal Fluorescence Microscope
Ra, H., Piyawattanametha, W., Gonzalez-Gonzalez, E., Mandella, M. J., Kino, G. S., Solgaard, O., … Contag, C. H. (2011). In Vivo Imaging of Human and Mouse Skin with a Handheld Dual-Axis Confocal Fluorescence Microscope. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131(5), 1061–66. -
Role of the basement membrane zone in skin development.
Oro, A. E. (2008). Role of the basement membrane zone in skin development. Journal of Investigative Dermatology, 128(E2), E11–2. -
Cell Migration: GSK3 beta Steers the Cytoskeleton's Tip
Yucel, G., & Oro, A. E. (2011). Cell Migration: GSK3 beta Steers the Cytoskeleton's Tip. CELL, 144(3), 319–21. -
SnapShot: Hair Follicle Stem Cells
Woo, W.-M., & Oro, A. E. (2011). SnapShot: Hair Follicle Stem Cells. CELL, 146(2), 334–U159. -
Neuropilins are positive regulators of Hedgehog signal transduction
Hillman, R. T., Feng, B. Y., Ni, J., Woo, W.-M., Milenkovic, L., Gephart, M. G. H., … Scott, M. P. (2011). Neuropilins are positive regulators of Hedgehog signal transduction. GENES & DEVELOPMENT, 25(22), 2333–46. -
Shh maintains dermal papilla identity and hair morphogenesis via a Noggin-Shh regulatory loop
Woo, W.-M., Zhen, H. H., & Oro, A. E. (2012). Shh maintains dermal papilla identity and hair morphogenesis via a Noggin-Shh regulatory loop. GENES & DEVELOPMENT, 26(11), 1235–46. -
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., … Hauschild, A. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 366(23), 2171–2179. -
Translocation Affecting Sonic Hedgehog Genes in Basal-Cell Carcinoma
Gomez-Ospina, N., Chang, A. L. S., Qu, K., & Oro, A. E. (2012). Translocation Affecting Sonic Hedgehog Genes in Basal-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 366(23), 2233–2234. -
Hedgehog pathway inhibition and the race against tumor evolution
Atwood, S. X., Chang, A. L. S., & Oro, A. E. (2012). Hedgehog pathway inhibition and the race against tumor evolution. JOURNAL OF CELL BIOLOGY, 199(2), 193–97. -
GLI activation by atypical protein kinase C ?/? regulates the growth of basal cell carcinomas.
Atwood, S. X., Li, M., Lee, A., Tang, J. Y., & Oro, A. E. (2013). GLI activation by atypical protein kinase C ?/? regulates the growth of basal cell carcinomas. Nature, 494(7438), 484–88. -
Rapid genetic analysis of epithelial-mesenchymal signaling during hair regeneration.
Woo, W.-M., Atwood, S. X., Zhen, H. H., & Oro, A. E. (2013). Rapid genetic analysis of epithelial-mesenchymal signaling during hair regeneration. Journal of Visualized Experiments : JoVE, (72). -
State-dependent signaling by Cav1.2 regulates hair follicle stem cell function.
Yucel, G., Altindag, B., Gomez-Ospina, N., Rana, A., Panagiotakos, G., Lara, M. F., … Oro, A. E. (2013). State-dependent signaling by Cav1.2 regulates hair follicle stem cell function. Genes & Development, 27(11), 1217–22. -
Hedgehog/patched signaling in animal development and disease
Scott, M. P., Goodrich, L. V., Higgins, K. M., Johnson, R. L., Milenkovic, L., & Oro, A. E. (1997). Hedgehog/patched signaling in animal development and disease. FASEB JOURNAL, 11(9), A1302–A1302. -
Induction of features of basal cell epithelioma in transgenic human skin expressing sonic Hedgehog in vivo.
Fan, H., Oro, A. E., Scott, M. P., & Khavari, P. A. (1997). Induction of features of basal cell epithelioma in transgenic human skin expressing sonic Hedgehog in vivo. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), 38–38. -
Hedgehog pathway inhibition and the race against tumor evolution
Atwood, S. X., Chang, A. L. S., & Oro, A. E. (2013). Hedgehog pathway inhibition and the race against tumor evolution. JOURNAL OF CELL BIOLOGY, 45–49. -
A perivascular stem cell niche in the hair follicle
Xiao, Y., Woo, W., Terunuma, A., Oro, A. E., Vogel, J. C., & Brownell, I. (2012). A perivascular stem cell niche in the hair follicle. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC: NATURE PUBLISHING GROUP. -
Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4
Gonzalez-Quevedo, R., Shoffer, M., Horng, L., & Oro, A. E. (2005). Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 124(4), A103–A103. -
MOLECULAR ANALYSIS OF THE INHERITANCE AND STABILITY OF THE MITOCHONDRIAL GENOME OF AN INBRED LINE OF MAIZE
Oro, A. E., Newton, K. J., & Walbot, V. (1985). MOLECULAR ANALYSIS OF THE INHERITANCE AND STABILITY OF THE MITOCHONDRIAL GENOME OF AN INBRED LINE OF MAIZE. THEORETICAL AND APPLIED GENETICS, 70(3), 287–293. -
Augmenting Endogenous Wnt Signaling Improves Skin Wound Healing
Whyte, J. L., Smith, A. A., Liu, B., Manzano, W. R., Evans, N. D., Dhamdhere, G. R., … Helms, J. A. (2013). Augmenting Endogenous Wnt Signaling Improves Skin Wound Healing. PLOS ONE, 8(10). -
Partial Proteasome Inhibitors Induce Hair Follicle Growth by Stabilizing ß-Catenin.
Yucel, G., Van Arnam, J., Means, P. C., Huntzicker, E., Altindag, B., Lara, M. F., … Oro, A. E. (2014). Partial Proteasome Inhibitors Induce Hair Follicle Growth by Stabilizing ß-Catenin. Stem Cells , 32(1), 85–92. -
"Atypical" regulation of Hedgehog-dependent cancers.
Atwood, S. X., & Oro, A. E. (2014). "Atypical" regulation of Hedgehog-dependent cancers. Cancer Cell, 25(2), 133–34. -
Somatic Correction of Junctional Epidermolysis Bullosa by a Highly Recombinogenic AAV Variant.
Melo, S. P., Lisowski, L., Bashkirova, E., Zhen, H. H., Chu, K., Keene, D. R., … Oro, A. E. (2014). Somatic Correction of Junctional Epidermolysis Bullosa by a Highly Recombinogenic AAV Variant. Molecular Therapy : the Journal of the American Society of Gene Therapy, 22(4), 725–33. -
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., … Cho, Y.-J. (2014). Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 20(7), 732–40. -
Advanced treatment for basal cell carcinomas.
Atwood, S. X., Whitson, R. J., & Oro, A. E. (2014). Advanced treatment for basal cell carcinomas. Cold Spring Harbor Perspectives in Medicine, 4(7). -
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., … Cho, Y.-J. (2014). Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. NATURE MEDICINE, 20(7), 732–40. -
Epigenetic targeting of hedgehog pathway transcriptional output.
Cho, Y.-J. J., Tang, Y., Schubert, S., Willardson, M., Bandopadhayay, P., Bergthold, G., … Cho, Y.-J. J. (2014). Epigenetic targeting of hedgehog pathway transcriptional output. Neuro-Oncology, 16 Suppl 3, iii25. -
Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa
Sebastiano, V., Zhen, H. H., Derafshi, B. H., Bashkirova, E., Melo, S. P., Wang, P., … Oro, A. E. (2014). Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. SCIENCE TRANSLATIONAL MEDICINE, 6(264). -
Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration
Woo, W.-M., Atwood, S. X., Zhen, H. H., & Oro, A. E. (2013). Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, (72). -
Smoothened variants explain the majority of drug resistance in Basal cell carcinoma.
Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., … Tang, J. Y. (2015). Smoothened variants explain the majority of drug resistance in Basal cell carcinoma. Cancer Cell, 27(3), 342–53. -
Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.
Atwood, S. X., Sarin, K. Y., Li, J. R., Yao, C. Y., Urman, N. M., Chang, A. L. S., … Oro, A. E. (2015). Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. Journal of Investigative Dermatology, 135(8), 2138–41. -
An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally, M. S., Aasi, S., Wysong, A., Teng, C., Anderson, E., Bailey-Healy, I., … Tang, J. Y. (2014). An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. Journal of the American Academy of Dermatology, 71(5), 904–11 e1. -
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., … Colevas, A. D. (2016). Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatology, 152(4), 452–56. -
Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma
Sarin, K. Y., Ally, M. S., Ransohoff, K. J., Atwood, S. X., & Rezaee, M. (2016). Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatology, 1–5. -
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Danial, C., Sarin, K. Y., Oro, A. E., & Chang, A. L. S. (2016). An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. CLINICAL CANCER RESEARCH, 22(6), 1325–29. -
Role of the Basement Membrane Zone in Skin Development.
Oro, A. E. (2008). Role of the Basement Membrane Zone in Skin Development. Journal of Investigative Dermatology, 128, E11–2. -
GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas
Atwood, S. X., Li, M., Lee, A., Tang, J. Y., & Oro, A. E. (2013). GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. NATURE, 494(7438), 484–88. -
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., … King, B. A. (2016). Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1(15). -
Soil Primes the Seed: Epigenetic Landscape Drives Tumor Behavior.
Whitson, R. J., & Oro, A. E. (2017). Soil Primes the Seed: Epigenetic Landscape Drives Tumor Behavior. Cell Stem Cell, 20(2), 149–50. -
Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions
Urman, N. M., Mirza, A., Atwood, S. X., Whitson, R. J., Sarin, K. Y., Tang, J. Y., & Oro, A. E. (2016). Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. PLOS ONE, 11(12). -
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Mirza, A. N., Fry, M. A., Urman, N. M., Atwood, S. X., Roffey, J., Ott, G. R., … Oro, A. E. (2017). Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight, 2(21). -
Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.
Whitson, R. J., Lee, A., Urman, N. M., Mirza, A., Yao, C. Y., Brown, A. S., … Oro, A. E. (2018). Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. Nature Medicine, 24(3), 271–81. -
Factors That May Promote an Effective Local Research Environment
Wang, K., Lee, C. S., Marinkovich, M. P., Chang, H. Y., Oro, A. E., & Khavari, P. A. (2016). Factors That May Promote an Effective Local Research Environment. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 136(8), 1529–31. -
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Crispin, M. K., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., … King, B. A. (2016). Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI INSIGHT, 1(15). -
OVERCOMING ACQUIRED AND A PRIORI RESISTANCE TO SMO ANTAGONISTS THROUGH EPIGENETIC REGULATION OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT
Tang, Y., Schubert, S., Brian Nguyen, Masoud, S., Gholamin, S., Lee, A., … Cho, Y.-J. (2014). OVERCOMING ACQUIRED AND A PRIORI RESISTANCE TO SMO ANTAGONISTS THROUGH EPIGENETIC REGULATION OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
TGF-beta, Fibronectin and Integrin alpha5beta1 Promote Invasion in Basal Cell Carcinoma.
Kuonen, F., Surbeck, I., Sarin, K. Y., Dontenwill, M., Ruegg, C., Gilliet, M., … Gaide, O. (2018). TGF-beta, Fibronectin and Integrin alpha5beta1 Promote Invasion in Basal Cell Carcinoma. The Journal of Investigative Dermatology. -
Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility
Cho, H. G., Kuo, K. Y., Li, S., Bailey, I., Aasi, S., Chang, A. L. S., … Sarin, K. Y. (2018). Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. JCI INSIGHT, 3(15). -
Actin polymerization controls cilia-mediated signaling
Drummond, M. L., Li, M., Tarapore, E., Nguyen, T. T. L., Barouni, B. J., Cruz, S., … Atwood, S. X. (2018). Actin polymerization controls cilia-mediated signaling. JOURNAL OF CELL BIOLOGY, 217(9), 3255–66. -
Retinoic acid and BMP4 cooperate with p63 to alter chromatin dynamics during surface epithelial commitment.
Pattison, J. M., Melo, S. P., Piekos, S. N., Torkelson, J. L., Bashkirova, E., Mumbach, M. R., … Oro, A. E. (2018). Retinoic acid and BMP4 cooperate with p63 to alter chromatin dynamics during surface epithelial commitment. Nature Genetics. -
LAP2 Proteins Chaperone GLI1 Movement between the Lamina and Chromatin to Regulate Transcription.
Mirza, A. N., McKellar, S. A., Urman, N. M., Brown, A. S., Hollmig, T., Aasi, S. Z., & Oro, A. E. (2018). LAP2 Proteins Chaperone GLI1 Movement between the Lamina and Chromatin to Regulate Transcription. Cell. -
MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias.
Brown, A. S., Meera, P., Altindag, B., Chopra, R., Perkins, E. M., Paul, S., … Oro, A. E. (2018). MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias. Proceedings of the National Academy of Sciences of the United States of America. -
TFAP2C- and p63-Dependent Networks Sequentially Rearrange Chromatin Landscapes to Drive Human Epidermal Lineage Commitment.
Li, L., Wang, Y., Torkelson, J. L., Shankar, G., Pattison, J. M., Zhen, H. H., … Oro, A. E. (2019). TFAP2C- and p63-Dependent Networks Sequentially Rearrange Chromatin Landscapes to Drive Human Epidermal Lineage Commitment. Cell Stem Cell. -
Loss of primary cilia drives switching from Hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma.
Kuonen, F., Huskey, N. E., Shankar, G., Jaju, P., Whitson, R. J., Rieger, K. E., … Oro, A. E. (2019). Loss of primary cilia drives switching from Hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma. The Journal of Investigative Dermatology. -
Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression
Sekulic, A., Hainsworth, J. D., Lewis, K. D., Oro, A. E., Gesierich, A., Mortier, L., … Fisher, D. (2015). Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. MOSBY-ELSEVIER. -
Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.
Sekulic, A., Hainsworth, J. D., Lewis, K. D., Oro, A. E., Gesierich, A., Mortier, L., … Hauschild, A. (2014). Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Lewis, K. D., Sekulic, A., Hauschild, A., Migden, M. R., Oro, A. E., LoRusso, P., … Von Hoff, D. D. (2014). Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Regulation of growth by the patched tumor suppressor gene.
Wechsler-Reya, R., Milenkovic, L., Goodrich, L. V., Oro, A. E., Higgins, K. M., & Scott, M. P. (1998). Regulation of growth by the patched tumor suppressor gene. DEVELOPMENTAL BIOLOGY. ACADEMIC PRESS INC. -
AAV-Mediated Direct Somatic Genetic Correction of Epidermolysis Bullosa
Melo, S., Lisowski, L., Bashkirova, L., Kay, M. A., & Oro, A. E. (2013). AAV-Mediated Direct Somatic Genetic Correction of Epidermolysis Bullosa. MOLECULAR THERAPY. NATURE PUBLISHING GROUP. -
Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)
Kwon, G. P., Ally, M. S., Bailey-Healy, I., Oro, A. E., Kim, J., Chang, A. L., … Tang, J. Y. (2016). Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 75(1), 213–15. -
Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
Chang, A. L. S., & Oro, A. E. (2012). Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma. ARCHIVES OF DERMATOLOGY, 148(11), 1324–25. -
TFAP2C-and p63-Dependent Networks Sequentially Rearrange Chromatin Landscapes to Drive Human Epidermal Lineage Commitment
Li, L., Wang, Y., Torkelson, J. L., Shankar, G., Pattison, J. M., Zhen, H. H., … Oro, A. E. (2019). TFAP2C-and p63-Dependent Networks Sequentially Rearrange Chromatin Landscapes to Drive Human Epidermal Lineage Commitment. CELL STEM CELL, 24(2), 271-+. -
Retinoic acid and BMP4 cooperate with p63 to alter chromatin dynamics during surface epithelial commitment
Pattison, J. M., Melo, S. P., Piekos, S. N., Torkelson, J. L., Bashkirova, E., Mumbach, M. R., … Oro, A. E. (2018). Retinoic acid and BMP4 cooperate with p63 to alter chromatin dynamics during surface epithelial commitment. NATURE GENETICS, 50(12), 1658-+. -
Genetic mutations underlying phenotypic plasticity in basosquamous carcinoma
Chiang, A., Tan, C. Z., Kuonen, F., Hodgkinson, L. M., Chiang, F., Cho, R. J., … Sarin, K. Y. (2019). Genetic mutations underlying phenotypic plasticity in basosquamous carcinoma. Journal of Investigative Dermatology. -
Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma
Kuonen, F., Huskey, N. E., Shankar, G., Jaju, P., Whitson, R. J., Rieger, K. E., … Oro, A. E. (2019). Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 139(7), 1439–48. -
LAP2 Proteins Chaperone GLI1 Movement between the Lamina and Chromatin to Regulate Transcription
Mirza, A. N., McKellar, S. A., Urman, N. M., Brown, A. S., Hollmig, T., Aasi, S. Z., & Oro, A. E. (2019). LAP2 Proteins Chaperone GLI1 Movement between the Lamina and Chromatin to Regulate Transcription. CELL, 176(1-2), 198-+. -
Receptor protein tyrosine phosphatases control Purkinje neuron firing.
Brown, A. S., Meera, P., Quinones, G., Magri, J., Otis, T. S., Pulst, S. M., & Oro, A. E. (2019). Receptor protein tyrosine phosphatases control Purkinje neuron firing. Cell Cycle (Georgetown, Tex.), 1–7. -
Starve a cold, and perhaps a cancer.
Haensel, D., & Oro, A. E. (2020). Starve a cold, and perhaps a cancer. Nature Cell Biology. -
AP-1 and TGFSS cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma.
Yao, C. D., Haensel, D., Gaddam, S., Patel, T., Atwood, S. X., Sarin, K. Y., … Oro, A. E. (2020). AP-1 and TGFSS cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma. Nature Communications, 11(1), 5079. -
The Sky's the LEMit: New insights into nuclear structure regulation of transcription factor activity.
Mirza, A. N., Gonzalez, F., Ha, S. K., & Oro, A. E. (2020). The Sky's the LEMit: New insights into nuclear structure regulation of transcription factor activity. Current Opinion in Cell Biology, 68, 173–80. -
Dermatology in the postgenomic era - Harnessing human variation for personalized medicine
Oro, A. E. (2008). Dermatology in the postgenomic era - Harnessing human variation for personalized medicine. ARCHIVES OF DERMATOLOGY, 144(3), 389–391. -
Modulation of the Hedgehog signaling pathway in models of basal cell carcinoma by ATP-competitive PKCi inhibitors
Roffey, J., Dillon, C., Oro, A. E., Mirza, A. N., Sarin, K. Y., Aasi, S. Z., … Ator, M. (2018). Modulation of the Hedgehog signaling pathway in models of basal cell carcinoma by ATP-competitive PKCi inhibitors. MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH. -
MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias
Brown, A. S., Meera, P., Altindag, B., Chopra, R., Perkins, E. M., Paul, S., … Oro, A. E. (2018). MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 115(52), E12407–E12416. -
TGF beta, Fibronectin and Integrin alpha 5 beta 1 Promote Invasion in Basal Cell Carcinoma
Kuonen, F., Surbeck, I., Sarin, K. Y., Dontenwill, M., Ruegg, C., Gilliet, M., … Gaide, O. (2018). TGF beta, Fibronectin and Integrin alpha 5 beta 1 Promote Invasion in Basal Cell Carcinoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(11), 2432–2442. -
Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update
Sekulic, A., Migden, M. R., Oro, A. E., Lewis, K. D., Hainsworth, J. D., Yoo, S., … Hauschild, A. (2012). Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma
Sekulic, A., Oro, A. E., Solomon, J. A., Hainsworth, J. D., Lewis, K., Dirix, L., & Migden, M. R. (2012). A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. MOSBY-ELSEVIER. -
C-FOS drives reversible basal to squamous cell carcinoma transition
Kuonen, F., Li, N., Haensel, D., Patel, T., Gaddam, S., Yerly, L., … Oro, A. (2021). C-FOS drives reversible basal to squamous cell carcinoma transition. JOURNAL OF INVESTIGATIVE DERMATOLOGY. ELSEVIER SCIENCE INC. -
Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.
Kilgour, J. M., Shah, A., Urman, N. M., Eichstadt, S., Do, H. N., Bailey, I., … Sarin, K. Y. (2021). Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Biomedical Data Commons (BMDC) prioritizes B-lymphocyte non-coding genetic variants in Type 1 Diabetes.
Piekos, S. N., Gaddam, S., Bhardwaj, P., Radhakrishnan, P., Guha, R. V., & Oro, A. E. (2021). Biomedical Data Commons (BMDC) prioritizes B-lymphocyte non-coding genetic variants in Type 1 Diabetes. PLoS Computational Biology, 17(9), e1009382. -
c-FOS drives reversible basal to squamous cell carcinoma transition.
Kuonen, F., Li, N. Y., Haensel, D., Patel, T., Gaddam, S., Yerly, L., … Oro, A. E. (2021). c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Reports, 37(1), 109774. -
Is hypoimmunogenic stem cell therapy safe in times of pandemics?
Matheus, F., Raveh, T., Oro, A. E., Wernig, M., & Drukker, M. (2022). Is hypoimmunogenic stem cell therapy safe in times of pandemics? Stem Cell Reports. -
Gibbin mesodermal regulation patterns epithelial development.
Collier, A., Liu, A., Torkelson, J., Pattison, J., Gaddam, S., Zhen, H., … Oro, A. E. (2022). Gibbin mesodermal regulation patterns epithelial development. Nature. -
A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs.
Shue, Y. T., Drainas, A. P., Li, N. Y., Pearsall, S. M., Morgan, D., Sinnott-Armstrong, N., … Sage, J. (2022). A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs. Nature Communications, 13(1), 2690.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms »
- Topical Itraconazole in Treating Patients With Basal Cell Cancer »
- A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies »
- Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms »
- A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma »
- Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) »
- Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors »
- Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma »
Practice Locations
High-Risk Skin Cancer Clinic Redwood City, CA
Redwood City, CA
High-Risk Skin Cancer Clinic
450 Broadway Street, Pavilion B, 4th Floor
Redwood City , CA 94063
Make An Appointment More Clinic Information » Getting Here »Hair Loss Clinic Redwood City, CA
Redwood City, CA
Hair Loss Clinic
450 Broadway Street, Pavilion B, 4th Floor
Redwood City , CA 94063
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(82 reviews)
Great drs, and very good checkin and checkout experience
Dr Oro is so sweet and caring. He’s helped me so much. I’m grateful to him!
Dr. Oro is kind, patient and very helpful.
Dr. Oro is a superb physician. As an MD I am well qualified to judge this.
As I said before, both doctors were wonderful.
I was given a prescription that have a bold warning on it that says it is not to be given to women.!
Knowledgeable, caring, friendly, confident.
Excellent experience.
Dr. Oro is excellent! I really appreciate the time he takes to address my concerns and questions along with the information he provides.
Excellent experience - "listening" doctors. Explained things in an understandable way.
I received excellent attention and care form Drs. A Chiang & Dr. A Oro.
I want to recognize the excellent and caring treatment provided by the resident during the biopsy procedure. Her technique and finesse during the procedure was the best I've ever received, and I've had this procedure too many times. Bravo!
Dr. Tu and Dr. Oro were very pleasant, caring and knowledgeable. It was a great experience meeting and understanding my health concern from both doctors.
Really felt support by provider as well as the wonderful residence provider.
Very friendly, could explain most of my problems & provided a potential solution to my problems.
Dr. Oro is a kind, compassionate, extremely knowledgeable and smart doctor. I consider myself very lucky to be under his care.
I was very happy to have finally seen Dr. Oro and got good advice and care -
Would recommend except for difficulty of getting an appt.
I felt that I learned a lot about my condition and was given some good advice.
Dr ORO is excellent, on time and very patient
Dr. Oro is the best doctor I have ever been to.
Dr Oro is friendly, engaging and knowledgeable.
I give Dr. Oro himself high marks. He's very personable and I didn't realize how scalp dermatology works. Systems of the body don't all work in the same way. I especially liked that he prescribed several things this second appointment including an antibiotic for the scalp to be sure no "bad germs" (my words) aren't addressed. So now I have the full arsenal! I'm still slightly skeptical of a full "cure" but time will tell.
very friendly and open. able to ask all questions. skin check too quick but resident was thorough
Exceptionally clear explanations.
Impersonal, few questions asked about history of problem discussion regarding care or treatment was non existent, seemed hurried and not involved or caring, at all.
I was seen by two doctors, and they were both excellent!
Doctor and resident doctor seemed very good. I am hard of hearing, however, and while resident adjusted her speaking so I could understand her well, doctor had a hard time doing that, speaking exceedingly fast at times.
Dr. Oro is wonderful.
excellent explanations, recommendations and speaking to me as medically informed consumer (physician)--appropriate level of discussion/recommendations (not too basic or too advanced).
Dr. Oro is the most fun doctor!!
I would have liked Dr. Oro to sit across from me instead of by my side. It's easier for conversation & I would have remembered questions I forgot.
Dr. Oro was great! I appreciated his calming demeanor, and his patience with my chief complaint, very friendly & immediately gained my trust.
I waited 5 months to see Dr. Oro! He was horrible, didn't talk to me, check my labs, or examine me. Had his 2nd year resident do everything including the biopsy. Didn't answer any questions. Didn't answer my phone calls or emails. Never follow up with me post biopsy. He is an awful doctor!
Thanks for answering my questions on the app! I sent photos and you confirmed which products were good and bad.
Dr. Oro has been my family care provider for many years. He is very competent and attentive to our needs. We have a very high regard for him!
Great doctor.
dr Anthony Oro is one of the best doctors I have seen. highly recommend him. he was extremely nice , knowledgeable and took his time explaining things to me. very caring and empathetic. A PLUS!
good
Very nice and considerate to patients.
dr oro is great!
Dr. Oro is an outstanding. I am very fortunate to be under his care. My condition has improved dramatically with his expert care.
Dr Oro is a splendid doctor and has great people skills as part of his practice.
Dr. Oro showed extreme concern for my situation an was very clear on how I was to proceed.
good
Care provider not only best in terms if medical care but listens, cares. Remembers past care history. reassuring.
Dr. Oro is amazing. He has the best bed side manner and seems knowledgeable. I feel comfortable with him.
So kind & attentive.
Love Dr. Ko & Dr. Oro - great care!
Dr. was excellent she was very attentive in my case and she helped me a lot professional and patient excellent.
I recommend Dr Oro and his residents all the time. I'm not even sure if he accepts new patients but I still recommend him. One of the best M.D.'s I ever encountered. One of my favorite people on the planet. :)
I really like my visit with doctor Oro. he is a great asset to your organization.
Have had nothing but positive interactions with doctor as well as the residents.
Dr. Oro cares about his patients and responds extremely well to their needs. He is outstanding!!! He is kind!
The best of any other.
Dr. Oro is amazing thank you. Will recommend to friends or family.
Dr. Oro is THE BEST!
Doctor very busy, did not have time for long term prognosis or current research question. I felt 'dismissed', not taken seriously.
Was in a hurry!
Dr. Oro is an excellent MD.
Typically, very happy with Dr. Oro. on this particular day, he was rushing very behind (no problem) but it was the end of the day and I wasn't given a full, thorough skin check like in the past - concerning.
Dr. Oro also answered an email question I sent via my health. Very helpful in managing my medications.
Thoughtful, concerned, and caring.
Both primary & resident were outstanding in all areas.
Dr. Oro is excellent.
The appointment felt VERY rushed, as did the visual body exam.
Dr. Oro is one of the best doctors I have ever seen. He is always caring and makes me eel I am important.
Dr. Oro is an outstanding physician. I have complete confidence in his expertise. I consider myself very fortunate to be able to see such a highly qualified physician. He is the model of what a physician should be.
Very happy with Dr. Oro.
Wonderful physician too harried, rushed.
Experience with this dr. and his staff was very good.
Dr. Oro always is excellent, answers all questions.
Excellent doctor, compassionate, good communication skills, state of the art knowledge.
Dr. Oro is a wonderfully caring physician. Although my derm. issue isn't serious Dr. Oro (& the residents) treat my concerns seriously & are supportive in trying to treat my chronic problem. Love Dr. Oro!
Very good.
Doctor and PA very kind and helpful. Excellent experience!
Dr. Oro is an outstanding physician. It is a privilege to be his patient.
Dr. Oro is wonderful - Excellent bedside manner and treated me with respect and compassion.
Dr. Oro was very directive and understanding. I would recommend him to others.
Like I said before Dr. Oro is the best!
Dr. Oro was great - took time to listen and really cared about my problem and spent QUALITY time with me!
Doctor and assistant very professional and caring.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
- Send referrals online
- View referral status
- Access medical records